Kiora Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Will Present Additional Data From Its ABACUS-1 Trial of KIO-301 in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Kiora Pharmicals 宣佈將在 ARVO 2024 年年會上公佈其針對色素性視網膜炎的 KIO-301 的 ABACUS-1 試驗的更多數據後,該公司股價走高